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In the latest issue of the JTCVS, Brescia and colleagues1 have approached a delicate subject: replace or 
repair a rheumatic mitral valve (MV)? For degenerative mitral valve disease, there is large evidence 
and overall consensus on the fact that valve repair is better than replacement. Certainly, every modern 
mitral valve surgeon approaches a degenerative MV regurgitation with a repair in mind and would try 
to avoid a replacement in most of these valves. However, the treatment for rheumatic mitral valve 
(RMV) disease differs according to the pathology of the valve and even the geographical regions. 
Starting from this background, the authors have retrospectively analysed their data on RMV comparing 
two different eras with a primary composite outcome of death, reoperation and severe valve 
dysfunction1. Their hypothesis is that a change in approach of the anterior leaflet (AL) had a significant 
impact on the results: indeed around 2009 their surgical approach to RMV changed and included a 
systematic echocardiographic and intraoperative assessment specifically dedicated to the AL. This new 
approach altered the operative decision-making process leading to a lower threshold for replacement 
when the AL was rigid or calcified (70% repair rate in Era 1 vs 33% in Era 2)1. This process was 
successful as the operative Era 1 was the strongest independent predictor of the primary outcome. These 
results are very important and confirm a very recent propensity matched report that support the evidence 
that rheumatic  mitral  valve  repair  in selected patients is superior to mitral valve replacement2. The 
study from Brescia et al1, although not representing the largest series of RMV, clearly defines an 
effective method of planning the surgical strategy that is not influenced by the presence and degree of 
mitral valve regurgitation alone. Similar to previous articles3, there was no significant difference in 
mortality between mitral valve repair group and replacement group, though it has to be acknowledged 
that vast majority of the reoperations were related to repairs. This tells us that repairing rheumatic  
valves could be difficult in certain cases and that is why we see a slight benefit for the replacement 
group in terms of composite outcome, although not statistically significant. It has to be recognised that 
some limitations are present in this study. One important limit of the study is related to the longer follow 
up of Era 1 that might have affected the number of events simply because the patients of this Era had a 
longer period of exposure. Moreover, one factor impacting on the primary outcome was the presence 
of preoperative atrial fibrillation and we can see that Era 1 had a significant higher number of patients 
with this concomitant disease. Therefore, some preoperative differences and time related characteristics 
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might have affected the results of the study, but despite these limitations, the study proposes a novel 
approach to RMV surgical planning and can guide us in determining which patients would benefits the 
most from a repair. At the end of the day, this all we want to know when treating RMV and this study 
is an important addition to the current knowledge on this topic. In conclusion, we congratulate with the 
authors for the nice study and the relevant work done in improving their decision-making process and 
therefore the indication for replacement: the benefits for the patients are already evident and an 
important lesson has been learned.  
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